Abstract:Background: The status of lymph nodes is crucial to determine the dose of radioiodine-131( 131 I) for postoperative papillary thyroid carcinoma (PTC). We aimed to develop a nomogram for predicting residual and recurrent cervical lymph node metastasis (CLNM) in postoperative PTC before 131 I therapy. Method: Data from 612 postoperative PTC patients who underwent 131 I therapy from May 2019 to December 2020 were retrospectively analyzed. Clinical and ultrasound features were collected. Univariate and multivariate logistic regression analyses were performed to determine the risk factors of CLNM. Receiver operating characteristic (ROC) analysis was used to weigh the discrimination of prediction models. To generate nomograms, models with high area under the curves (AUC) were selected. Bootstrap internal validation, calibration curves and decision curves were used to assess the prediction model's discrimination, calibration, and clinical usefulness. Results: A total of 18.79% (115/612) of postoperative PTC patients had CLNM. Univariate logistic regression analysis found serum thyroglobulin (Tg), serum thyroglobulin antibodies (TgAb), overall ultrasound diagnosis and seven ultrasound features (aspect transverse ratio, cystic change, microcalcification, mass hyperecho, echogenicity, lymphatic hilum structure and vascularity) were significantly associated with CLNM. Multivariate analysis revealed higher Tg, higher TgAb, positive overall ultrasound and ultrasound features such as aspect transverse ratio ≥ 2, microcalcification, heterogeneous echogenicity, absence of lymphatic hilum structure and abundant vascularity were independent risk factors for CLNM. ROC analysis showed the use of Tg and TgAb combined with ultrasound (AUC = 0.903 for "Tg+TgAb+Overall ultrasound" model, AUC = 0.921 for "Tg+TgAb+Seven ultrasound features" model) was superior to any single variant. Nomograms constructed for the above two models were validated internally and the C-index were 0.899 and 0.914, respectively. Calibration curves showed satisfied discrimination and calibration of the two nomograms. DCA also proved that the two nomograms were clinically useful. Conclusion: Through the two accurate and easy-to-use nomograms, the possibility of CLNM can be objectively quantified before 131 I therapy. Clinicians can use the nomograms to evaluate the status of lymph nodes in postoperative PTC patients and consider a higher dose of 131 I for those with high scores.

Analysis of correlation factors influencing the outcome of initial 131I remnant ablative therapy in intermediate- to high-risk patients with papillary thyroid microcarcinoma

Important Parameters Should Be Paid Attention in PTMC Radiofrequency Ablation

Preoperative Serum Thyroglobulin Levels Predict Radioiodine Therapy Outcome in Papillary Thyroid Microcarcinoma Patients

Papillary Thyroid Micro Carcinoma: The Incidence of High-Risk Features and Its Prognostic Implications.

Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect

The impact of lymph node metastatic rate on clinical outcome following131I therapy in patients with papillary thyroid carcinoma

Analysis of Influential Factors for Efficacy of 131Ⅰ Thyroid Remnant Ablation for Differentiated Thyroid Carcinoma

Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study

Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation

Blood prognostic predictors of treatment response for patients with papillary thyroid cancer

The impact of thyroglobulin antibody on efficacy of131I ablation in patients with papillary thyroid carcinoma

Prognostic Factors for Excellent Response to Initial Therapy in Patients With Papillary Thyroid Cancer From a Prospective Multicenter Study

In Patients with Low- to Intermediate-Risk Thyroid Cancer, A Preablative Thyrotropin Level of 30 Mu Iu/Ml is Not Adequate to Achieve Better Response to I-131 Therapy

Analysis on the factors affecting the efficacy of 131Ⅰ remnant ablation in patients after thyroidectomy for differentiated thyroid carcinoma

Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study

In Patients with Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 Μiu/ml is Not Adequate to Achieve Better Response to 131I Therapy.

Cervical lymph node metastasis prediction of postoperative papillary thyroid carcinoma before 131I therapy based on clinical and ultrasound characteristics

Improving the Risk Prediction of the 2015 ATA Recurrence Risk Stratification in Papillary Thyroid Cancer

Stimulating Thyroglobulin to TSH Ratio Predict Long-Term Efficacy of 131 I Therapy in Patients with Differentiated Thyroid Cancer after Total Thyroidectomy: a Retrospective Study

Outcome of Radioiodine Therapy in Patients with Papillary Thyroid Carcinoma Concurrent with Hashimoto's Thyroiditis

Clinical Outcomes of Ultrasound-Guided Radiofrequency Ablation for the Treatment of Primary Papillary Thyroid Microcarcinoma